Genenta Science (GNTA) Competitors $5.45 +0.35 (+6.86%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNTA vs. MGTX, TSHA, ORGO, VYGR, RNAC, SNDL, AMLX, YSB, CYRX, and AKBAShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include MeiraGTx (MGTX), Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Voyager Therapeutics (VYGR), Cartesian Therapeutics (RNAC), SNDL (SNDL), Amylyx Pharmaceuticals (AMLX), YS Biopharma (YSB), Cryoport (CYRX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. MeiraGTx Taysha Gene Therapies Organogenesis Voyager Therapeutics Cartesian Therapeutics SNDL Amylyx Pharmaceuticals YS Biopharma Cryoport Akebia Therapeutics Genenta Science (NASDAQ:GNTA) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Do institutionals and insiders hold more shares of GNTA or MGTX? 15.1% of Genenta Science shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is GNTA or MGTX more profitable? Genenta Science has a net margin of 0.00% compared to MeiraGTx's net margin of -1,146.81%. Genenta Science's return on equity of 0.00% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A MeiraGTx -1,146.81%-152.82%-56.41% Do analysts prefer GNTA or MGTX? Genenta Science presently has a consensus price target of $25.00, suggesting a potential upside of 358.72%. MeiraGTx has a consensus price target of $22.50, suggesting a potential upside of 287.26%. Given Genenta Science's higher possible upside, equities research analysts clearly believe Genenta Science is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, GNTA or MGTX? Genenta Science has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Does the MarketBeat Community prefer GNTA or MGTX? MeiraGTx received 182 more outperform votes than Genenta Science when rated by MarketBeat users. However, 87.50% of users gave Genenta Science an outperform vote while only 71.32% of users gave MeiraGTx an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%MeiraGTxOutperform Votes18971.32% Underperform Votes7628.68% Which has better earnings & valuation, GNTA or MGTX? Genenta Science has higher earnings, but lower revenue than MeiraGTx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/AMeiraGTx$8.12M46.42-$84.03M-$1.40-4.15 Does the media prefer GNTA or MGTX? In the previous week, Genenta Science's average media sentiment score of 0.46 beat MeiraGTx's score of 0.00 indicating that Genenta Science is being referred to more favorably in the media. Company Overall Sentiment Genenta Science Neutral MeiraGTx Neutral SummaryGenenta Science beats MeiraGTx on 8 of the 13 factors compared between the two stocks. Ad Porter & CompanyThis is treasonIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.30M$3.15B$5.54B$8.53BDividend YieldN/A1.77%5.13%4.14%P/E RatioN/A11.73114.8115.14Price / SalesN/A397.851,495.55100.10Price / CashN/A148.6639.6734.08Price / Book4.504.024.665.02Net Income-$12.60M-$42.25M$119.06M$225.46M7 Day Performance4.32%8.04%0.80%0.37%1 Month Performance21.92%8.69%5.65%3.57%1 Year Performance8.57%32.09%36.75%29.43% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.4806 of 5 stars$5.45+6.9%$25.00+358.7%+2.1%$99.30MN/A0.007Gap UpMGTXMeiraGTx4.4545 of 5 stars$5.86+1.0%$22.50+284.0%+15.3%$380.31M$14.02M-4.19300TSHATaysha Gene Therapies1.6547 of 5 stars$1.99+1.0%$6.38+220.4%-35.8%$372.17M$12.87M-9.95180News CoverageORGOOrganogenesis4.0766 of 5 stars$2.80-2.4%$4.88+74.1%+21.4%$371.20M$448.39M-21.54950News CoverageVYGRVoyager Therapeutics4.2127 of 5 stars$6.75+2.7%$17.43+158.2%+6.9%$367.16M$143.77M24.11100Upcoming EarningsAnalyst UpgradeRNACCartesian Therapeutics3.3474 of 5 stars$20.58-6.9%$43.00+108.9%N/A$366.24M$54.10M0.0037Positive NewsSNDLSNDL3.3274 of 5 stars$2.18+3.3%$3.63+66.3%+46.5%$361.92M$911.92M-6.812,516Upcoming EarningsAMLXAmylyx Pharmaceuticals4.0918 of 5 stars$5.31+8.4%$14.57+174.4%-67.0%$361.11M$298.76M-2.17200Positive NewsYSBYS Biopharma1.4561 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773CYRXCryoport2.515 of 5 stars$6.89+2.2%$12.00+74.2%-24.9%$339.38M$225.61M-1.881,170Upcoming EarningsShort Interest ↑News CoverageAKBAAkebia Therapeutics4.0531 of 5 stars$1.59+0.6%$5.75+261.6%+91.6%$333.26M$174.50M-7.57167Short Interest ↓News Coverage Related Companies and Tools Related Companies MeiraGTx Competitors Taysha Gene Therapies Competitors Organogenesis Competitors Voyager Therapeutics Competitors Cartesian Therapeutics Competitors SNDL Competitors Amylyx Pharmaceuticals Competitors YS Biopharma Competitors Cryoport Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
